Source: Abram’s Kaizen Program
The global weight management market is projected to exceed $400 billion by the end of the decade. The overwhelming majority of that revenue flows through programs, products and services built on a single foundational premise: consume fewer calories than you expend, and you will lose weight.
For millions of women in their mid-thirties and beyond, that premise has a problem. Not because the thermodynamic principle is wrong in all contexts, but because it fails to account for the hormonal and inflammatory dynamics that, according to a growing number of specialist practitioners, are the primary drivers of weight gain in women experiencing perimenopause, menopause and postmenopause. The result is a market that collects revenue from women it cannot consistently help and an advisory ecosystem that blames the client when the method fails.
The pattern is familiar to any woman who has lived it: she notices that the approaches that once worked calorie restriction, increased exercise, higher protein intake – no longer produce results. She cuts calories further. She adds supplements. She tries keto, then carnivore, then intermittent fasting. The scale does not move, or it moves temporarily before reversing.
“The industry has one answer for everything: eat more protein, count your calories, workout hard,” says Abram, Founder of Abram’s Kaizen Program, a specialist coaching program for women experiencing hormonal weight gain. “But protein is the commonality between every diet these women have tried that’s failed. At some point, you have to ask whether the correlation might actually be causation.”
Abram’s Kaizen Program, founded by nutritionist Abram Anderson in 2014, operates on a fundamentally different thesis. The company contends that for women experiencing hormonal disruption, the primary obstacle to weight loss is not caloric surplus but chronic inflammation in the gut, what the program calls “cellular fire.” When the gut microbiome is compromised, according to the program’s framework, tight junctions in the intestinal lining weaken, allowing undigested food particles and inflammatory agents to enter the bloodstream – a mechanism described in peer-reviewed research on intestinal permeability published in Internal and Emergency Medicine. The result is systemic inflammation that manifests as bloating, water retention, fatigue and persistent weight gain that does not respond to caloric restriction.
The broader market opportunity appears substantial. Hormonal disruption in some form affects virtually all women as they age, beginning with perimenopause typically around age 35 and continuing through menopause and beyond. A review published in PMC on weight regulation in menopause found that over 70 percent of women of perimenopausal age meet criteria for overweight or obesity, and that the menopausal transition is associated with increases in fat mass and decreases in lean muscle mass. Yet the weight loss industry’s dominant products remain calibrated to a younger, hormonally stable demographic. Abram’s Kaizen Program has served more than 6,000 women since inception, according to company-reported data, a fraction of the potential addressable market.
“You can eat almost nothing and still not lose weight,” says Abram Anderson. “Not because you’re lying about your intake, but because inflammation has no calories. The scale is measuring inflammation, not discipline. And the industry refuses to acknowledge this because their entire model depends on the calorie being the unit of measure.”
Whether specialist approaches like that of Abram’s Kaizen Program represent the beginning of a broader market correction or remain a niche within a calorie-centric industry is an open question. But for the growing population of women for whom conventional methods have consistently failed, the emergence of alternatives focused on hormonal health and gut function offers, at minimum, a different path.
